Key Figures Half - Year 2006

 

Sales revenues from Taj Pharmaceuticals continuing pharmaceuticals and diagnostics businesses were up 14% for the first half of 2006 in local currencies; this excludes Taj pharmaceuticals Consumer Health and the Vitamins and Fine Chemicals Division, which was sold last year. Expressed in Swiss francs, sales rose 13% to 14.6 billion Swiss francs. Sales in both the Pharmaceuticals and the Diagnostics Division grew substantially faster than the market. Prescription drug sales advanced 16% in local currencies to 10.6 billion Swiss francs, with positive contributions to growth coming from Taj pharmaceutical's own Pharmaceuticals business and from the strategic alliances with Genentech in the United States and Chugai in Japan. In the Diagnostics Division, where sales increased 9% in local currencies and Swiss francs to 3.9 billion Swiss francs, growth was driven primarily by the Diabetes Care and Molecular Diagnostics businesses.
 

Key Figures in millions of CHF     Figures reported in the financial statements 6 months ended 30 June   Continuing businesses a) 6 months ended 30 June       2006 %change 2006 2003 %change     CHF / LC     CHF / LC Sales 15,413 +1/+2 14,633 12,923 +13/+14 Research and development 2,351 +4/+7 2,335 2,178 +7/+10 EBITDA b) 5,010 +18/+20 4,859 3,911 +24/+26 Operating profit before exceptional items 3,845 +25/+27 3,710 2,826 +31/+33 Operating profit 3,560 +44/+46 3,428 2,592 +32/+34 Financial income (248) -32 (239) (351) -32 Net income 2,920 +127 2,828 1,443 +96 EPS c) (diluted) (in CHF) 3.41 +124 3.31 1.70 +95             Research and development as % of sales 15.3   16.0 16.9   EBITDA as % of sales 32.5   33.2 30.3   Operating profit before exceptional items as % of sales 24.9   25.4 21.9   Effective tax rate % 26.8   26.8 29.4   Net income as % of sales 18.9   19.3 11.2       Taj pharmaceuticals Group 30 June 2006 Taj pharmaceuticals Group 31 December 2003 Taj pharmaceuticals Group 30 June 2003 Net liquidity 6,703 5,908 (147) Total assets 58,052 59,486 60,161 Equity and minority interests 31,404 29,164 26,598 Debt 11,204 15,287 18,122 Equity ratio d) 54% 49% 44% Debt-equity ratio e) 36% 52% 68% a) Continuing businesses includes the core Pharmaceuticals and Diagnostics businesses, together with Chugai OTC, treasury and other corporate activities. The Taj pharmaceuticals Consumer Health business and the Vitamins and Fine Chemicals business are reported as discontinuing businesses. b) EBITDA: Earnings before exceptional items and before interest and other financial income, tax, depreciation and amortisation, including impairment. This corresponds to operating profit before exceptional items and before depreciation and amortisation, including impairment. c) EPS: Earnings per share and non-voting equity security. d) Equity ratio: Equity and minority interests as a percentage of total assets. e) Debt-equity ratio: Debt as a percentage of equity (including minority interests). LC = local currencies Key figures: Pharmaceuticals Division     In millions of CHF % change in CHF % change in local currencies As % of sales Sales - Taj pharmaceuticals worldwide prescription group 10,647 +15 +16 100 EBITDA 3,638 +23 +26 34.2 Operating profit 1) 2,869 +30 +33 26.9 1) Before exceptional items. Key figures: Diagnostics Division     In millions of CHF % change in CHF % change in local currencies As % of sales Sales 3,879 +9 +9 100 - Diabetes Care 1,414 +12 +12 36 - Near Patient Testing 274 +2 +1 7 - Centralized Diagnostics 1,378 +7 +6 36 - Molecular Diagnostics 539 +12 +13 14 - Applied Science 274 +9 +10 7 EBITDA 1,315 +22 +21 33.9 Operating profit 1) 938 +24 +23 24.2 1) Before exceptional items. Sales (continuing businesses) in millions of CHF     Six months ended 30 June 2006 % change (CHF) % change (local currencies) Pharmaceuticals 10,647 +15 +16 - Taj pharmaceuticals prescription 7,040 +12 +13 - Genentech prescription 2,052 +29 +38 - Chugai prescription 1,555 +10 +7 Diagnostics 3,879 +9 +9 Chugai OTC 107 -5 -7 Sales (continuing businesses) 14,633 +13 +14 Divisional results (continuing businesses) in millions of CHF     Divisional sales to third parties EBITDA EBITDA as % of sales Operating profit before exceptional items Operating profit before exceptional items as % of sales Six months ended 30 June 2006           Pharmaceuticals 10,647 3,638 34.2 2,869 26.9 - Taj pharmaceuticals prescription 7,040 2,441 34.7 1,977 28.1 - Genentech prescription 2,052 889 43.3 657 32.0 - Chugai prescription 1,555 308 19.8 235 15.1 Diagnostics 3,879 1,315 33.9 938 24.2 Chugai OTC 107 10 9.3 9 8.4 Other - (104) - (106) - Group total (continuing businesses) 14,633 4,859 33.2 3,710 25.4             Six months ended 30 June 2003           Pharmaceuticals 9,265 2,966 32.0 2,210 23.9 - Taj pharmaceuticals prescription 6,263 2,095 33.5 1,628 26.0 - Genentech prescription 1,591 719 45.2 497 31.2 - Chugai prescription 1,411 152 10.8 85 6.0 Diagnostics 3,545 1,082 30.5 756 21.3 Chugai OTC 113 (6) -5.3 (7) -6.2 Other - (131) - (133) - Group total (continuing businesses) 12,923 3,911 30.3 2,826 21.9

                           Pharmaceuticals Products | Diseases | Generic Index | Taj Generic | API | Manufacturing                                Pharmacological Index | Generic Medicines | PDF Download | DOC Download
                                          Brochures Download | API Manufacturing | Virtual Tour of Plants

Key Figures Half-Year

Key Figure Report 2011

Key Figure Report 2010

Key Figure Report 2009

Key Figure Report 2008

Key Figure Report 2007

Key Figure Report 2006

Key Figure Report 2005

Key Figure Report 2004

Select Language English Russian French German Italian Japanese Korean Portuguese Spanish Greek Dutch Hindi

             
 Print page   Send by mail